Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of vonoprazan OD vs conventional tablet in Japanese healthy males
jRCT1080224521Phase 1Completed
- Sponsor
- Takeda
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan in Acid Peptic Disease (APD) (4 arms), sponsored by Takeda. Primary endpoint: Bioequivalence of vonoprazan OD 20 mg vs vonoprazan 20 mg tablet. Started Jan 2019; status: completed.
02
Drugs
vonoprazan
03
Conditions
Acid Peptic Disease (APD)
Beyond the preview
Go deeper on jRCT1080224521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224521.